JP2008502706A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008502706A5 JP2008502706A5 JP2007516856A JP2007516856A JP2008502706A5 JP 2008502706 A5 JP2008502706 A5 JP 2008502706A5 JP 2007516856 A JP2007516856 A JP 2007516856A JP 2007516856 A JP2007516856 A JP 2007516856A JP 2008502706 A5 JP2008502706 A5 JP 2008502706A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cells
- group
- syndrome
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims 39
- 210000004027 cell Anatomy 0.000 claims 14
- 239000002245 particle Substances 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 7
- 210000001519 tissue Anatomy 0.000 claims 7
- 208000011580 syndromic disease Diseases 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- -1 antifungal Substances 0.000 claims 4
- 239000006185 dispersion Substances 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 206010003591 Ataxia Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000026350 Inborn Genetic disease Diseases 0.000 claims 2
- 208000009905 Neurofibromatoses Diseases 0.000 claims 2
- 206010057249 Phagocytosis Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 201000000582 Retinoblastoma Diseases 0.000 claims 2
- 206010043189 Telangiectasia Diseases 0.000 claims 2
- 208000037919 acquired disease Diseases 0.000 claims 2
- 239000000464 adrenergic agent Substances 0.000 claims 2
- 229930013930 alkaloid Natural products 0.000 claims 2
- 229940100198 alkylating agent Drugs 0.000 claims 2
- 239000002168 alkylating agent Substances 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 229940088710 antibiotic agent Drugs 0.000 claims 2
- 210000003651 basophil Anatomy 0.000 claims 2
- 210000002449 bone cell Anatomy 0.000 claims 2
- 210000002798 bone marrow cell Anatomy 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 2
- 235000014633 carbohydrates Nutrition 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000000812 cholinergic antagonist Substances 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 210000004443 dendritic cell Anatomy 0.000 claims 2
- 239000000032 diagnostic agent Substances 0.000 claims 2
- 229940039227 diagnostic agent Drugs 0.000 claims 2
- 210000003979 eosinophil Anatomy 0.000 claims 2
- 210000003743 erythrocyte Anatomy 0.000 claims 2
- 210000003714 granulocyte Anatomy 0.000 claims 2
- 239000001963 growth medium Substances 0.000 claims 2
- 210000002540 macrophage Anatomy 0.000 claims 2
- 210000001616 monocyte Anatomy 0.000 claims 2
- 210000000663 muscle cell Anatomy 0.000 claims 2
- 201000004931 neurofibromatosis Diseases 0.000 claims 2
- 210000002569 neuron Anatomy 0.000 claims 2
- 210000000440 neutrophil Anatomy 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 230000008782 phagocytosis Effects 0.000 claims 2
- 230000008884 pinocytosis Effects 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 230000002685 pulmonary effect Effects 0.000 claims 2
- 239000000932 sedative agent Substances 0.000 claims 2
- 238000001179 sorption measurement Methods 0.000 claims 2
- 239000000021 stimulant Substances 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 208000009056 telangiectasis Diseases 0.000 claims 2
- 210000005167 vascular cell Anatomy 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 208000010543 22q11.2 deletion syndrome Diseases 0.000 claims 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims 1
- 208000003200 Adenoma Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000024985 Alport syndrome Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000037663 Best vitelliform macular dystrophy Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 1
- 208000008448 Congenital adrenal hyperplasia Diseases 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 206010053138 Congenital aplastic anaemia Diseases 0.000 claims 1
- 208000026372 Congenital cystic kidney disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000026292 Cystic Kidney disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- 101710088194 Dehydrogenase Proteins 0.000 claims 1
- 208000013558 Developmental Bone disease Diseases 0.000 claims 1
- 208000000398 DiGeorge Syndrome Diseases 0.000 claims 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims 1
- 201000003542 Factor VIII deficiency Diseases 0.000 claims 1
- 201000004939 Fanconi anemia Diseases 0.000 claims 1
- 208000015872 Gaucher disease Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000012777 Hartnup Disease Diseases 0.000 claims 1
- 208000009292 Hemophilia A Diseases 0.000 claims 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims 1
- 208000028782 Hereditary disease Diseases 0.000 claims 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 208000015439 Lysosomal storage disease Diseases 0.000 claims 1
- 208000024556 Mendelian disease Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000014060 Niemann-Pick disease Diseases 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims 1
- 208000004843 Pendred Syndrome Diseases 0.000 claims 1
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims 1
- 241000097929 Porphyria Species 0.000 claims 1
- 208000010642 Porphyrias Diseases 0.000 claims 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims 1
- 208000006289 Rett Syndrome Diseases 0.000 claims 1
- 206010072610 Skeletal dysplasia Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 239000000150 Sympathomimetic Substances 0.000 claims 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- 208000002903 Thalassemia Diseases 0.000 claims 1
- 208000026911 Tuberous sclerosis complex Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 206010049644 Williams syndrome Diseases 0.000 claims 1
- 208000018839 Wilson disease Diseases 0.000 claims 1
- 238000002441 X-ray diffraction Methods 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000001919 adrenal effect Effects 0.000 claims 1
- 230000001800 adrenalinergic effect Effects 0.000 claims 1
- 239000000674 adrenergic antagonist Substances 0.000 claims 1
- 230000003281 allosteric effect Effects 0.000 claims 1
- 239000003263 anabolic agent Substances 0.000 claims 1
- 229940070021 anabolic steroids Drugs 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 229940035674 anesthetics Drugs 0.000 claims 1
- 239000003945 anionic surfactant Substances 0.000 claims 1
- 230000000954 anitussive effect Effects 0.000 claims 1
- 229940069428 antacid Drugs 0.000 claims 1
- 239000003159 antacid agent Substances 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 230000000507 anthelmentic effect Effects 0.000 claims 1
- 230000001466 anti-adreneric effect Effects 0.000 claims 1
- 230000001430 anti-depressive effect Effects 0.000 claims 1
- 230000001142 anti-diarrhea Effects 0.000 claims 1
- 230000003432 anti-folate effect Effects 0.000 claims 1
- 230000000843 anti-fungal effect Effects 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 230000001022 anti-muscarinic effect Effects 0.000 claims 1
- 230000001355 anti-mycobacterial effect Effects 0.000 claims 1
- 230000000389 anti-prion effect Effects 0.000 claims 1
- 230000000842 anti-protozoal effect Effects 0.000 claims 1
- 230000002921 anti-spasmodic effect Effects 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 claims 1
- 229940055075 anticholinesterase parasympathomimetics Drugs 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- 229940125681 anticonvulsant agent Drugs 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 239000003793 antidiarrheal agent Substances 0.000 claims 1
- 229940125714 antidiarrheal agent Drugs 0.000 claims 1
- 239000000729 antidote Substances 0.000 claims 1
- 229940075522 antidotes Drugs 0.000 claims 1
- 229940127074 antifolate Drugs 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 229940030225 antihemorrhagics Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 239000003926 antimycobacterial agent Substances 0.000 claims 1
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003904 antiprotozoal agent Substances 0.000 claims 1
- 239000002221 antipyretic Substances 0.000 claims 1
- 239000003435 antirheumatic agent Substances 0.000 claims 1
- 229940124584 antitussives Drugs 0.000 claims 1
- 239000002249 anxiolytic agent Substances 0.000 claims 1
- 230000000949 anxiolytic effect Effects 0.000 claims 1
- 239000002830 appetite depressant Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 239000003093 cationic surfactant Substances 0.000 claims 1
- 239000006143 cell culture medium Substances 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 238000002059 diagnostic imaging Methods 0.000 claims 1
- 238000000113 differential scanning calorimetry Methods 0.000 claims 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
- 229940005501 dopaminergic agent Drugs 0.000 claims 1
- 230000002124 endocrine Effects 0.000 claims 1
- 201000011523 endocrine gland cancer Diseases 0.000 claims 1
- 239000002532 enzyme inhibitor Substances 0.000 claims 1
- 239000004052 folic acid antagonist Substances 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 239000003193 general anesthetic agent Substances 0.000 claims 1
- 208000016361 genetic disease Diseases 0.000 claims 1
- 208000005594 glucose-galactose malabsorption Diseases 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- 230000010370 hearing loss Effects 0.000 claims 1
- 231100000888 hearing loss Toxicity 0.000 claims 1
- 208000016354 hearing loss disease Diseases 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 239000002874 hemostatic agent Substances 0.000 claims 1
- 208000003215 hereditary nephritis Diseases 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000003326 hypnotic agent Substances 0.000 claims 1
- 239000012216 imaging agent Substances 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000003607 modifier Substances 0.000 claims 1
- 239000000472 muscarinic agonist Substances 0.000 claims 1
- 239000003176 neuroleptic agent Substances 0.000 claims 1
- 239000002736 nonionic surfactant Substances 0.000 claims 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000734 parasympathomimetic agent Substances 0.000 claims 1
- 230000001499 parasympathomimetic effect Effects 0.000 claims 1
- 229940005542 parasympathomimetics Drugs 0.000 claims 1
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 150000003180 prostaglandins Chemical class 0.000 claims 1
- 239000012217 radiopharmaceutical Substances 0.000 claims 1
- 229940121896 radiopharmaceutical Drugs 0.000 claims 1
- 230000002799 radiopharmaceutical effect Effects 0.000 claims 1
- 239000003087 receptor blocking agent Substances 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 229940125723 sedative agent Drugs 0.000 claims 1
- 230000001624 sedative effect Effects 0.000 claims 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000001975 sympathomimetic effect Effects 0.000 claims 1
- 229940064707 sympathomimetics Drugs 0.000 claims 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 208000009999 tuberous sclerosis Diseases 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 201000007790 vitelliform macular dystrophy Diseases 0.000 claims 1
- 208000020938 vitelliform macular dystrophy 2 Diseases 0.000 claims 1
- 208000006542 von Hippel-Lindau disease Diseases 0.000 claims 1
- 210000004885 white matter Anatomy 0.000 claims 1
- 239000002888 zwitterionic surfactant Substances 0.000 claims 1
Claims (33)
- 薬学的に活性な因子の小さい粒子の調製、および哺乳動物被験体への該粒子の送達のための組成物であって、該組成物は、1種以上の治療的活性のある化合物または診断剤の粒子を含む薬学的組成物を含み、ここで該組成物は、細胞培養培地中で哺乳動物ドナーに由来する組織細胞に添加され、該細胞による該細胞の細胞内区画のいずれかへの該粒子の取り込み、該細胞の周囲への該粒子の付着、またはそれらの組み合わせを生じ、該哺乳動物被験体への投与に適している、組成物。
- 前記組成物は、前記哺乳動物被験体の標的組織への前記細胞の送達による投与に適している、請求項1に記載の組成物。
- 前記組成物は、静脈内に、筋肉内に、皮下に、皮内に、関節内に、クモ膜下腔内に、硬膜外に、大脳内に、頬側に、直腸に、局所に、経皮的に、経口で、鼻腔内に、肺経路から、腹腔内に、眼内に、またはそれらの組み合わせでの投与に適している、請求項1に記載の組成物。
- 前記細胞は、ファゴサイトーシス、粒子の吸着、またはこれらの粒子のピノサイトーシスの能力を有する、請求項1に記載の組成物。
- 前記細胞が、マクロファージ、単球、顆粒球、好中球、好塩基球、好酸球、樹状細胞およびそれらの組み合わせからなる群より選択される、請求項1に記載の組成物。
- 前記細胞が、赤血球、筋細胞、骨髄細胞および骨細胞、血管細胞、臓器組織細胞、神経細胞、樹状細胞およびそれらの組み合わせからなる群より選択される、請求項1に記載の組成物。
- 前記粒子の一部は、前記標的組織への送達の前に溶解してしまうことはない、請求項2に記載の組成物。
- 前記薬学的組成物は、前記化合物の飽和溶解度を上回る粒子の濃度を有している、請求項1に記載の組成物。
- 前記化合物は、水に難溶性である、請求項1に記載の組成物。
- 前記細胞は、24時間以上にわたって培養される、請求項1に記載の組成物。
- 前記薬学的組成物は、さらに界面活性剤を含む、請求項1に記載の組成物。
- 前記界面活性剤は、陰イオン性界面活性剤、陽イオン性界面活性剤、両性イオン性界面活性剤、非イオン性界面活性剤、表面活性のある生物学的改変因子、およびそれらの組み合わせからなる群より選択される、請求項11に記載の組成物。
- 前記薬学的組成物中の粒子は、示差走査熱量測定法またはX線回折のいずれかによって決定された場合に、不定形、半結晶性、結晶性、またはそれらの組み合わせである、請求項1に記載の組成物。
- 前記薬学的組成物は水混和性である、請求項1に記載の組成物。
- 前記治療因子は、鎮痛薬、麻酔薬、興奮薬、アドレナリン作動薬、アドレナリン遮断薬、抗アドレナリン薬、アドレノコルチコイド、アドレナリン模倣物、抗コリン作動剤、抗コリンエステラーゼ、抗痙攣剤、アルキル化剤、アルカロイド、アロステリックインヒビター、蛋白同化ステロイド、食欲抑制薬、制酸剤、止瀉薬、解毒剤、葉酸代謝拮抗薬、解熱剤、抗リウマチ剤、精神治療薬、神経遮断薬、抗炎症薬、駆虫薬、抗生物質、抗凝固剤、抗鬱剤、鎮痙薬、抗真菌剤、抗ヒスタミン剤、抗ムスカリン剤、抗ミコバクテリア剤、抗腫瘍薬、抗原虫薬、抗ウイルス薬、抗不安鎮静薬、β−アドレナリン受容体遮断薬、造影剤、コルチコステロイド、鎮咳剤、診断剤、画像診断剤、ドーパミン作動薬、止血剤、血液学的薬剤、催眠薬、免疫学的薬剤、ムスカリン様作用薬、副交感神経作用薬、プロスタグランジン、プロテアーゼインヒビター、放射性薬品、鎮静剤、刺激薬、交感神経刺激剤、ビタミン、キサンチン、増殖因子、ホルモン、抗プリオン薬、およびそれらの組み合わせからなる群より選択される、請求項10に記載の組成物。
- 前記抗腫瘍薬は、パクリタキセルとその誘導化合物、アルカロイド、代謝拮抗物質、酵素インヒビター、アルキル化剤、抗生物質、遺伝子治療薬、およびそれらの組み合わせからなる群より選択される、請求項15に記載の組成物。
- 前記治療剤は、オリゴヌクレオチドおよび核酸からなる群より選択される、請求項10に記載の組成物。
- 前記治療剤は生物製剤である、請求項10に記載の組成物。
- 前記生物製剤は、タンパク質、ポリペプチド、炭水化物、ポリヌクレオチド、核酸、およびそれらの組み合わせからなる群より選択される、請求項18に記載の組成物。
- 前記タンパク質は、ポリクローナル抗体、モノクローナル抗体、およびそれらの組み合わせからなる群より選択される抗体である、請求項19に記載の組成物。
- 前記薬学的組成物の分散物は、投与の前に滅菌される、請求項1に記載の組成物。
- 前記治療活性のある化合物が、遺伝的に後天性の疾患または遺伝性の疾患を処置するために使用される、請求項9に記載の組成物。
- 前記遺伝的に後天性の疾患または遺伝性の疾患が、鎌状赤血球貧血、バーキットリンパ腫、ゴウシェ病、血友病A、慢性骨髄性白血病、ニーマンピック病、発作性夜間血色素尿症、ポルフィリン症、サラセミア、乳ガンおよび卵巣ガン、結腸ガン、小細胞肺癌、悪性黒色腫、多発性内分泌腫瘍、神経線維腫症、膵ガン、多発性嚢胞腎疾患、前立腺ガン、網膜芽細胞腫、結節硬化症、フォン・ヒッペル−リンダウ症候群、結腸ガン、クローン病、嚢胞性線維症、1型糖尿病、グルコース・ガラクトース吸収不全症、ウィルソン病、ツェルヴェーガー症候群、遺伝的に後天性の難聴、神経線維腫症、ペンドレッド症候群、ベスト病、遺伝的に後天性の緑内障、脳回転状網膜脈絡膜萎縮、網膜芽細胞腫、レット症候群、副腎過形成、先天性副腎白質ジストロフィ、自己免疫性多腺症候群、コケーン症候群、褶曲性骨形成異常、多発性内分泌腺腫、毛細血管拡張性運動失調、アテローム性動脈硬化症、QT延長症候群、ウィリアムズ症候群、喘息、毛細血管拡張性運動失調、ディジョージ症候群、高IgM症候群を伴う免疫不全症、重症複合型免疫不全、アルポート症候群、男性型禿頭症、前立腺ガン、ファンコーニ貧血、ハートナップ病、カルタゲナー症候群、リソソーム蓄積症、およびピルビン酸デヒドロゲナーゼ欠損症からなる群より選択される、請求項22に記載の組成物。
- 約100ミクロン未満の平均粒径を有している粒子として提供され、組織に到達することができる細胞による有効量の薬学的組成物の組織への送達のために哺乳動物被験体に投与するように適応された、該薬学的組成物の分散物を含む、該哺乳動物被験体への送達のための組成物。
- 前記細胞が、ファゴサイトーシス、細胞表面上での粒子としての前記薬学的組成物の吸着、ピノサイトーシス、またはそれらの組み合わせの可能性を有する、請求項24に記載の組成物。
- 前記細胞が、マクロファージ、単球、顆粒球、好中球、好塩基球、好酸球、幹細胞、樹状細胞、およびそれらの組み合わせからなる群より選択される、請求項24に記載の組成物。
- 前記細胞が、赤血球、筋細胞、骨髄細胞および骨細胞、血管細胞、臓器組織細胞、神経細胞、およびそれらの組み合わせからなる群より選択される、請求項24に記載の組成物。
- 前記薬学的組成物は、選択培養培地または非選択培養培地中で細胞と混合される、請求項24に記載の組成物。
- 前記治療剤は生物製剤である、請求項24に記載の組成物。
- 前記生物製剤は、タンパク質、ポリペプチド、炭水化物、ポリヌクレオチド、核酸、およびそれらの組み合わせからなる群より選択される、請求項29に記載の組成物。
- 前記タンパク質は、ポリクローナル抗体、モノクローナル抗体、およびそれらの組み合わせからなる群より選択される抗体である、請求項30に記載の組成物。
- 前記薬学的組成物の分散物は、静脈内に、筋肉内に、皮下に、皮内に、関節内に、クモ膜下腔内に、硬膜外に、大脳内に、頬側に、直腸に、局所に、経皮的に、経口で、鼻腔内に、肺経路から、腹腔内に、眼内に、眼窩球後に、またはそれらの組み合わせで送達される、請求項24に記載の組成物。
- 前記薬学的組成物の分散物が投与の前に滅菌されている、請求項24に記載の組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57989104P | 2004-06-15 | 2004-06-15 | |
PCT/US2005/022992 WO2005123907A2 (en) | 2004-06-15 | 2005-06-08 | Ex-vivo application of solid microparticulate therapeutic agents |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008502706A JP2008502706A (ja) | 2008-01-31 |
JP2008502706A5 true JP2008502706A5 (ja) | 2008-07-03 |
Family
ID=35169714
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007516856A Withdrawn JP2008502706A (ja) | 2004-06-15 | 2005-06-08 | 固体微粒子治療剤のエキソビボ適用 |
Country Status (13)
Country | Link |
---|---|
US (1) | US8333959B2 (ja) |
EP (1) | EP1763576A2 (ja) |
JP (1) | JP2008502706A (ja) |
KR (1) | KR20070037444A (ja) |
CN (1) | CN101310011A (ja) |
AU (1) | AU2005255039A1 (ja) |
BR (1) | BRPI0510271A (ja) |
CA (1) | CA2565972A1 (ja) |
IL (1) | IL177780A0 (ja) |
MX (1) | MXPA06011171A (ja) |
RU (1) | RU2006144851A (ja) |
WO (1) | WO2005123907A2 (ja) |
ZA (1) | ZA200610078B (ja) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004112747A2 (en) | 2003-06-24 | 2004-12-29 | Baxter International Inc. | Specific delivery of drugs to the brain |
US8986736B2 (en) | 2003-06-24 | 2015-03-24 | Baxter International Inc. | Method for delivering particulate drugs to tissues |
RU2006144851A (ru) | 2004-06-15 | 2008-06-20 | Бакстер Интернэшнл Инк. (Us) | Применение терапевтических средств ex-vivo в виде твердых микрочастиц |
US20070166386A1 (en) * | 2006-01-13 | 2007-07-19 | Chinea Vanessa I | Nanoparticle formation of pharmaceutical ingredients |
US8784846B2 (en) * | 2007-07-30 | 2014-07-22 | Loma Linda University Medical Center | Systems and methods for particle radiation enhanced delivery of therapy |
JP5331116B2 (ja) * | 2007-07-30 | 2013-10-30 | ローマ リンダ ユニヴァーシティ メディカル センター | 粒子放射線で増強された治療を供給するシステム及び方法 |
AU2008305516A1 (en) * | 2007-09-26 | 2009-04-02 | Anthrogenesis Corporation | Angiogenic cells from human placental perfusate |
EP2044934A1 (en) * | 2007-10-01 | 2009-04-08 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Dispersion of poloxamer-protein particles, methods of manufacturing and uses thereof |
EP2242507B1 (en) * | 2008-02-13 | 2013-02-20 | Erytech Pharma | Formulation and method for the prevention and treatment of skeletal manifestation of gaucher's disease |
EP2259798B1 (en) | 2008-03-05 | 2013-12-11 | Baxter International Inc. | Surface-modified particles and methods for targeted drug delivery |
JP2011518888A (ja) * | 2008-04-29 | 2011-06-30 | ザ ブライハム アンド ウイメンズ ホスピタル, インコーポレイテッド | 細胞膜改変 |
US20100042072A1 (en) * | 2008-08-13 | 2010-02-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Biological targeting compositions and methods of using the same |
US20100040546A1 (en) * | 2008-08-13 | 2010-02-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Biological targeting compositions and methods of using the same |
US8211656B2 (en) | 2008-08-13 | 2012-07-03 | The Invention Science Fund I, Llc | Biological targeting compositions and methods of using the same |
US10952965B2 (en) | 2009-05-15 | 2021-03-23 | Baxter International Inc. | Compositions and methods for drug delivery |
US8669533B2 (en) | 2009-10-01 | 2014-03-11 | Vladimir Bashkirov | Ion induced impact ionization detector and uses thereof |
WO2011047277A2 (en) * | 2009-10-15 | 2011-04-21 | The Brigham And Women's Hospital, Inc. | Release of agents from cells |
PT3626258T (pt) * | 2010-06-25 | 2021-10-19 | Shire Human Genetic Therapies | Métodos e composições para fornecimento ao snc de iduronato-2-sulfatase |
CN101926998B (zh) * | 2010-09-10 | 2013-09-04 | 中国科学院水生生物研究所 | 肾上腺素受体激动剂诱导胚胎型珠蛋白表达及其用途 |
US9717827B2 (en) | 2012-09-12 | 2017-08-01 | The Regents Of The University Of California | Immunomodulatory materials for implantable medical devices |
EP2906232A4 (en) * | 2012-10-15 | 2016-09-28 | Mark Frings Pittenger | DEVICE FOR EXTRACORPORAL CELL THERAPY OF THE LUNG OR OTHER ORGANS |
CA2930665A1 (en) | 2013-11-18 | 2015-05-21 | Rubius Therapeutics, Inc. | Synthetic membrane-receiver complexes |
CN107812197B (zh) * | 2014-09-20 | 2018-09-18 | 中国药科大学 | 一种炎症靶向的中性粒细胞递药系统及其应用 |
RU2633502C2 (ru) * | 2016-03-31 | 2017-10-12 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фундаментальной и клинической иммунологии" (НИИФКИ) | Способ инкорпорации биологически активных микро- и наночастиц в нейтрофилы |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US688436A (en) * | 1901-08-02 | 1901-12-10 | Oswald Richter | Fire-escape. |
DE2655801C2 (de) * | 1976-12-09 | 1986-06-26 | Kernforschungsanlage Jülich GmbH, 5170 Jülich | Injizierbare Suspension von Membranvesikeln aus Erythrozyten und Verfahren zur Herstellung der Suspension |
DE2656317C2 (de) * | 1976-12-11 | 1986-06-19 | Kernforschungsanlage Jülich GmbH, 5170 Jülich | Verfahren zur Herstellung einer Suspension von beladenen Erythrocyten |
DE2656746C2 (de) * | 1976-12-15 | 1986-06-26 | Kernforschungsanlage Jülich GmbH, 5170 Jülich | Verwendung von beladenen Erythrozyten |
US4608278A (en) * | 1983-06-22 | 1986-08-26 | The Ohio State University Research Foundation | Small particule formation and encapsulation |
US4826689A (en) * | 1984-05-21 | 1989-05-02 | University Of Rochester | Method for making uniformly sized particles from water-insoluble organic compounds |
CA1338736C (fr) * | 1986-12-05 | 1996-11-26 | Roger Baurain | Microcristaux comportant une substance active presentant une affinite pour les phospholipides, et au moins un phospholipide, procede de preparation |
FR2608988B1 (fr) * | 1986-12-31 | 1991-01-11 | Centre Nat Rech Scient | Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules |
US5213788A (en) | 1988-09-29 | 1993-05-25 | Ranney David F | Physically and chemically stabilized polyatomic clusters for magnetic resonance image and spectral enhancement |
FR2651680B1 (fr) * | 1989-09-14 | 1991-12-27 | Medgenix Group Sa | Nouveau procede de preparation de microparticules lipidiques. |
US5188837A (en) * | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
US5091188A (en) * | 1990-04-26 | 1992-02-25 | Haynes Duncan H | Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs |
DE69218403T2 (de) | 1991-01-07 | 1997-06-26 | Syngenix Ltd | Für endocytose geeignete teilchen |
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
ES2177549T3 (es) | 1992-09-28 | 2002-12-16 | Univ Brown Res Found | Matriz de nucleo de quitosano para celulas viables encapsuladas. |
US6090925A (en) * | 1993-03-09 | 2000-07-18 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
US5981719A (en) * | 1993-03-09 | 1999-11-09 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
US5720551A (en) * | 1994-10-28 | 1998-02-24 | Shechter; Tal | Forming emulsions |
SE9403846D0 (sv) * | 1994-11-09 | 1994-11-09 | Univ Ohio State Res Found | Small particle formation |
US5716642A (en) * | 1995-01-10 | 1998-02-10 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents |
US5560932A (en) * | 1995-01-10 | 1996-10-01 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents |
US5665331A (en) * | 1995-01-10 | 1997-09-09 | Nanosystems L.L.C. | Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers |
US5662883A (en) * | 1995-01-10 | 1997-09-02 | Nanosystems L.L.C. | Microprecipitation of micro-nanoparticulate pharmaceutical agents |
US6902743B1 (en) * | 1995-05-22 | 2005-06-07 | The United States Of America As Represented By The Secretary Of The Army | Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix |
WO1997002817A1 (en) * | 1995-07-13 | 1997-01-30 | University Of Cincinnati | Compounds useful in the treatment of neurofibromatosis |
US6143211A (en) * | 1995-07-21 | 2000-11-07 | Brown University Foundation | Process for preparing microparticles through phase inversion phenomena |
US6331299B1 (en) * | 1995-08-18 | 2001-12-18 | Sloan-Kettering Institute For Cancer Research | Method for treatment of cancer and infectious disease and compositions useful in same |
US20050054033A9 (en) * | 1995-08-30 | 2005-03-10 | Human Genome Sciences, Inc. | Methods and compositions for treating and preventing infection using human interferon regulatory factor 3 |
CA2234957C (en) | 1995-10-17 | 2006-12-19 | Inge B. Henriksen | Insoluble drug delivery |
JP2000514440A (ja) * | 1996-07-09 | 2000-10-31 | ザ ジョーンズ ホプキンス ユニバーシティー | 遺伝子輸送システム |
US6797813B2 (en) * | 1996-09-23 | 2004-09-28 | Schering Corporation | AK155 antibodies and binding fragments thereof |
US6045829A (en) * | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
WO1998035666A1 (en) * | 1997-02-13 | 1998-08-20 | Nanosystems Llc | Formulations of nanoparticle naproxen tablets |
AU7133898A (en) | 1997-04-18 | 1998-11-13 | Vertex Pharmaceuticals Incorporated | Nanosized aspartyl protease inhibitors |
US20020068048A1 (en) | 1997-09-05 | 2002-06-06 | Patrick A. Dreyfus | Method for the treatment or diagnosis of human pathologies with disseminated or difficult to access cells or tissues |
US6638621B2 (en) * | 2000-08-16 | 2003-10-28 | Lyotropic Therapeutics, Inc. | Coated particles, methods of making and using |
WO2000006244A2 (en) * | 1998-07-30 | 2000-02-10 | Hainfeld James F | Loading metal particles into cell membrane vesicles and metal particle use for imaging and therapy |
AU4476600A (en) * | 1999-04-22 | 2000-11-10 | Vanderbilt University | Polymeric encapsulation system promoting angiogenesis |
US20050112141A1 (en) * | 2000-08-30 | 2005-05-26 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
US6458387B1 (en) * | 1999-10-18 | 2002-10-01 | Epic Therapeutics, Inc. | Sustained release microspheres |
GB0002856D0 (en) | 2000-02-08 | 2000-03-29 | Gendel Limited | Ultrasound sensitisation |
EP1267946A4 (en) * | 2000-02-28 | 2008-07-02 | Genesegues Inc | SYSTEM AND METHOD FOR ENCAPSULATING NANOCAPSULES |
JP4085231B2 (ja) * | 2000-02-28 | 2008-05-14 | 株式会社ビークル | タンパク質中空ナノ粒子とそれを用いた物質運搬体、ならびに細胞への物質導入方法 |
US7338657B2 (en) * | 2001-03-15 | 2008-03-04 | Biosphere Medical, Inc. | Injectable microspheres for tissue construction |
JP2004511426A (ja) | 2000-05-03 | 2004-04-15 | ミュンヘン バイオテク アーゲー | 活性化血管部位に関連する陽イオン性の診断薬、画像化剤、および治療薬 |
US6455073B1 (en) * | 2000-07-10 | 2002-09-24 | Enzrel, Inc. | Covalent microparticle-drug conjugates for biological targeting |
US6627442B1 (en) * | 2000-08-31 | 2003-09-30 | Virxsys Corporation | Methods for stable transduction of cells with hiv-derived viral vectors |
ES2326209T3 (es) * | 2000-10-27 | 2009-10-05 | Baxter Healthcare S.A. | Produccion de microesferas. |
US7037528B2 (en) * | 2000-12-22 | 2006-05-02 | Baxter International Inc. | Microprecipitation method for preparing submicron suspensions |
EP1642571A3 (en) | 2000-12-22 | 2007-06-27 | Baxter International Inc. | Method for preparing submicron particle suspensions |
US9700866B2 (en) | 2000-12-22 | 2017-07-11 | Baxter International Inc. | Surfactant systems for delivery of organic compounds |
US6884436B2 (en) * | 2000-12-22 | 2005-04-26 | Baxter International Inc. | Method for preparing submicron particle suspensions |
US20040022861A1 (en) * | 2001-01-30 | 2004-02-05 | Williams Robert O. | Process for production of nanoparticles and microparticles by spray freezing into liquid |
WO2002060416A1 (en) * | 2001-02-01 | 2002-08-08 | Gendel Limited | Polypeptide delivery system and method for their preparation |
US20020169102A1 (en) | 2001-04-03 | 2002-11-14 | Frey William H. | Intranasal delivery of agents for regulating development of implanted cells in the CNS |
US6790455B2 (en) * | 2001-09-14 | 2004-09-14 | The Research Foundation At State University Of New York | Cell delivery system comprising a fibrous matrix and cells |
US20060003012A9 (en) * | 2001-09-26 | 2006-01-05 | Sean Brynjelsen | Preparation of submicron solid particle suspensions by sonication of multiphase systems |
GB0224442D0 (en) | 2002-10-21 | 2002-11-27 | Molmed Spa | A delivery system |
US20070053839A1 (en) * | 2003-06-12 | 2007-03-08 | Jianyi Zhang | Directing cells to target tissues organs |
PL1567188T3 (pl) * | 2003-06-20 | 2012-12-31 | Lilly Co Eli | Zmodyfikowane cząstki wirusa o właściwościach immunogennych i zmniejszonej zawartości lipidów użyteczne do leczenia i profilaktyki chorób zakaźnych |
WO2004112747A2 (en) * | 2003-06-24 | 2004-12-29 | Baxter International Inc. | Specific delivery of drugs to the brain |
US20050084456A1 (en) * | 2003-10-21 | 2005-04-21 | Liping Tang | Functionalized particles |
GB0329310D0 (en) * | 2003-12-18 | 2004-01-21 | Univ Keele | Method |
EP1713443A2 (en) | 2004-01-29 | 2006-10-25 | Baxter International Inc. | Nanosuspensions of anti-retroviral agents for increased central nervous system delivery |
DK2992901T3 (da) | 2004-02-02 | 2020-01-27 | Engeneic Molecular Delivery Pty Ltd | Sammensætninger og fremgangsmåder til målrettet in vitro- og in vivo-medicinlevering til pattedyrceller via bakterielt afledte intakte miniceller |
RU2006144851A (ru) | 2004-06-15 | 2008-06-20 | Бакстер Интернэшнл Инк. (Us) | Применение терапевтических средств ex-vivo в виде твердых микрочастиц |
CN1772303A (zh) | 2005-10-25 | 2006-05-17 | 朱宏 | 恶性肿瘤磁热疗用纳米磁粉-抗体靶向药物 |
-
2005
- 2005-06-08 RU RU2006144851/13A patent/RU2006144851A/ru not_active Application Discontinuation
- 2005-06-08 KR KR1020067026367A patent/KR20070037444A/ko not_active Application Discontinuation
- 2005-06-08 AU AU2005255039A patent/AU2005255039A1/en not_active Abandoned
- 2005-06-08 CA CA002565972A patent/CA2565972A1/en not_active Abandoned
- 2005-06-08 BR BRPI0510271-5A patent/BRPI0510271A/pt not_active IP Right Cessation
- 2005-06-08 JP JP2007516856A patent/JP2008502706A/ja not_active Withdrawn
- 2005-06-08 CN CNA200580017766XA patent/CN101310011A/zh active Pending
- 2005-06-08 WO PCT/US2005/022992 patent/WO2005123907A2/en active Application Filing
- 2005-06-08 EP EP05763705A patent/EP1763576A2/en not_active Withdrawn
- 2005-06-08 MX MXPA06011171A patent/MXPA06011171A/es unknown
- 2005-06-09 US US11/148,453 patent/US8333959B2/en active Active
-
2006
- 2006-08-30 IL IL177780A patent/IL177780A0/en unknown
- 2006-12-01 ZA ZA200610078A patent/ZA200610078B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2008502706A5 (ja) | ||
RU2006144851A (ru) | Применение терапевтических средств ex-vivo в виде твердых микрочастиц | |
CA2573245C (en) | Multivalent vla-4 antagonists comprising polymer moieties | |
Hamaguchi et al. | Phase I study of NK012, a novel SN-38–incorporating micellar nanoparticle, in adult patients with solid tumors | |
Bohannon et al. | Vincristine in the treatment of lymphomas and leukemias | |
Quintás‐Cardama et al. | Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009 | |
EP3046584B1 (en) | Therapeutic polymeric nanoparticles and methods of making and using same | |
Dabaja et al. | Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome | |
US8269009B2 (en) | Methods and compositions for treating liquid tumors | |
JP4554684B2 (ja) | 抗癌治療 | |
CN1390143A (zh) | 两亲型前药 | |
EP1140022B1 (en) | Method of administering a compound to multi-drug resistant cells | |
US8569426B2 (en) | Preparation of polymer conjugates of therapeutic, agricultural, and food additive compounds | |
US20200261596A1 (en) | Therapeutic Particles with Peptide Boronic Acid or Boronate Ester Compounds and Methods of Making and Using Same | |
Agrawal et al. | Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the “best” therapy? | |
Hamilton et al. | Improving Antibody‐Tubulysin Conjugates through Linker Chemistry and Site‐Specific Conjugation | |
Ochi et al. | A possible mechanism for the long-lasting antitumor effect of the macromolecular conjugate DE-310: mediation by cellular uptake and drug release of its active camptothecin analog DX-8951 | |
Gordon et al. | Macrophages as targets for drug delivery | |
Amato | Thalidomide: an antineoplastic agent | |
US20080213249A1 (en) | Use of Retro-Aldol Reaction to Generate Reactive Vinyl Ketone for Attachment to Antibody Molecules by Michael Addition Reaction for Use in Immunostaining and Immunotargeting | |
Crump et al. | Phase II study of sequential topotecan and etoposide in patients with intermediate grade non-Hodgkin's lymphoma: a National Cancer Institute of Canada Clinical Trials Group study | |
Boland et al. | Busulphan is active against neuroblastoma and medulloblastoma xenografts in athymic mice at clinically achievable plasma drug concentrations | |
TWI322010B (en) | Estrogen cancer therapy | |
US20160143914A1 (en) | Nanoparticles for Encapsulation and Delivery of Bioactive Compounds and Compositions Thereof | |
WO2022201063A1 (en) | Nanoparticle composition for targeted protein degradation |